A Product overview with focus on Rare Diseases.
AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.
Adasuve® is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Busilvex® is a concentrate used to conditioning treatment prior to stem cell transplantation.
Canemes® prevents nausea and vomiting in patients undergoing chemotherapy for malignant tumours and is used if other drugs do not have the desired effect.
Dystardis® is indicated for the treatment of moderate to severe late dyskinesia. Late dyskinesia is a disorder characterized by uncontrollable movements such as cramping in the stomach Face, making faces, or abnormal tongue movements.
Feraccru® is indicated for adults for the treatment of iron deficiency.
Ospolot® is an antiepileptic drug and is used to treat Rolandic epilepsy.
Remodulin® is used to treat idiopathic or hereditary pulmonary arterial hypertension (PAH) in patients with medium to severe symptoms.
Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologies such as tardive dyskinesia, tics and dystonia.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients
Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.